CBT-295

CBT-295 is an orally active autotaxin (ATX) inhibitor. CBT-295 exhibits a significant reduction in inflammatory cytokines like TGF-β, TNF-α and IL-6 levels, also reduced bile duct proliferation marker CK-19 and lowered liver fibrosis. The reversal of liver fibrosis with CBT-295 led to a reduction in blood and brain ammonia levels. CBT-295 also reduced neuroinflammation induced by ammonia. CBT-295 is promising for research of liver cirrhosis and associated encephalopathy[1].

Product Specifications

UNSPSC

12352005

Target

Interleukin Related; TGF-beta/Smad

Type

Reference compound

Related Pathways

Immunology/Inflammation; Stem Cell/Wnt; TGF-beta/Smad

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/cbt-295.html

Purity

99.34

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C1C=C(C)N(CCCCC)C2=NC(C3=CC=C(Cl)C=C3)=CN12

Molecular Formula

C18H20ClN3O

Molecular Weight

329.82

References & Citations

[1]Roy S, et al. Effect of an Autotaxin Inhibitor, 2- (4-Chlorophenyl) -7-methyl-8-pentylimidazo [1, 2-a] Pyrimidin-5 (8 H) -one (CBT-295), on Bile Duct Ligation-Induced Chronic Liver Disease and Associated Hepatic Encephalopathy in Rats[J]. ACS Pharmacology & Translational Science, 2024.